Editas Medicine Inc
NASDAQ:EDIT
Editas Medicine Inc
NASDAQ:EDIT
Price:
2.63
USD
0.77%
Market Cap:
$257.4m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Editas Medicine Inc
NASDAQ:EDIT
|
US |
|
Television Francaise 1 SA
PAR:TFI
|
FR |
|
P
|
Pernod Ricard SA
F:PER
|
FR |
|
GMK Noril'skiy Nikel' PAO
MOEX:GMKN
|
RU |
|
Adams PLC
LSE:ADA
|
IM |
|
Meta Platforms Inc
BMV:META
|
US |
|
Access Intelligence PLC
LSE:ACC
|
UK |
|
M
|
Medibank Private Ltd
F:MPV
|
AU |
|
Aimia Inc
TSX:AIM
|
CA |
|
F
|
Fraport Frankfurt Airport Services Worldwide AG
XMUN:FRA
|
DE |
|
J
|
John Menzies PLC
F:B3N
|
UK |
|
Service Stream Ltd
ASX:SSM
|
AU |
Multiples-Based Value
The
Multiples-Based Value for
Editas Medicine Inc (EDIT)
under the Base Case is
hidden
USD.
Compared with the current market price of 2.63 USD, the stock appears
hidden
.
Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
EDIT Multiples-Based Value
LOCKED
Multiples Across Competitors
EDIT Competitors Multiples
Editas Medicine Inc Competitors
Editas Medicine Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Editas Medicine Inc
NASDAQ:EDIT
|
255.4m USD | 6.4 | -1.6 | -1.8 | -1.7 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | -194 446.1 | -192 227.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
380.1B USD | 6 | 88.4 | 14.7 | 20.4 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
190.4B USD | 5.1 | 24.3 | 14.1 | 14.1 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
174.1B USD | 5.9 | 20.3 | 12.7 | 15.7 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
113.6B USD | 9.3 | 28.2 | 21.2 | 22.1 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | -581 | -565.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
82.2B USD | 5.6 | 17.7 | 13.1 | 15 | |
| AU |
|
CSL Ltd
ASX:CSL
|
68.5B AUD | 3.1 | 34 | 11.3 | 14.2 | |
| NL |
|
argenx SE
XBRU:ARGX
|
39.6B EUR | 11.3 | 36.2 | 39.3 | 40.1 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | -66.6 | -60.1 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
